Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ABCA4 pre-mRNA is the unspliced RNA intermediate transcribed from the ABCA4 gene, containing all exons and introns prior to RNA processing. Pathogenic variants in non-coding regions—especially deep intronic mutations—can disrupt normal splicing of ABCA4 pre-mRNA, resulting in aberrant mRNA and deficient ABCA4 protein production. This leads to loss of function in the ABCA4 transporter, a critical protein found in retinal photoreceptors. Such splicing defects are associated with inherited retinal diseases, most notably Stargardt disease. Recent approaches target ABCA4 pre-mRNA with antisense oligonucleotides as a therapeutic strategy to correct splicing errors and restore protein production.
Antisense oligonucleotides bind to ABCA4 pre-mRNA to modulate splicing and restore normal ABCA4 protein expression
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ABCA4 pre-mRNA.